Auxilium Pharmaceuticals — Investor Presentation (September 2008)
37 slides from Auxilium Pharmaceuticals's investor presentation, Sep 24, 2008
Slide 1: September 2008
Exhibit 99.1 September 2008
Slide 2: Safe Harbor Statement
Safe Harbor Statement Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to ma
Slide 3: Slide 3
Slide 4: Auxilium Pharmaceuticals, Inc.
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) • Specialty biopharmaceutical company focused on Urologists, Endocrinologists, Orthopedists and certain PCPs • Founded in 1999 • Headquarters in Malvern, Pa. – Manufacturing in Horsham, Pa. – Approximately 33
Slide 5: Anticipated News Flow Events
Anticipated News Flow Events 5 6 6 Q409 Q309 Q209 Q109 2010 Anticipated News Flow Events End of 2009: • XIAFLEX- Results of Peyronie's Phase IIb Study H109: • XIAFLEX- Open Label Dupuytren’s Contracture Safety Data Early 2009: • XIAFLEX- File BLA for Dupuytren's Contracture Early 2010 XIAFLEX – FDA
Slide 6: XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity
XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity • Potential to be first effective non-surgical treatment for two high unmet needs – Dupuytren’s contracture – Peyronie’s disease • Well-characterized mode of action • Worldwide rights offer opti
Slide 7: Dupuytren's Contracture—a Debilitating Condition
Dupuytren’s Contracture—a Debilitating Condition Dupuytren’s Contracture—a Debilitating Condition • Excessive collagen deposition • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Debilitating effect on quality of life • Surgery may be reser
Slide 8: Current Treatment Options Are Invasive or Ineffective
Current Treatment Options Are Invasive or Ineffective Current Treatment Options Are Invasive or Ineffective • Surgery • Non-surgical options – Splinting – Physical therapy – Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation
Slide 9: Dupuytren's Contracture—Unmet Medical Need
Dupuytren’s Contracture—Unmet Medical Need Dupuytren’s Contracture—Unmet Medical Need • Disease prevalence is estimated at 3%-6% among adult Caucasians, but occurs in all populations • Higher prevalence in patients of northern-European descent • Hereditary component in approximately 40% of patients
Slide 10: XIAFLEX—Potential to Revolutionize Treatment for Dupuytren's Contracture
XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture
Slide 11: XIAFLEX—Potential to Revolutionize Treatment for Dupuytren's Contracture
XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture
Slide 12: CORD I Design
CORD I Design CORD I Design • Largest ever double-blind, placebo-controlled trial in Dupuytren’s contracture – randomized in 2:1 ratio of active to placebo – enrolled a 2:1 ratio of MP:PIP – enrolled 1:1 ratio of less severe to more severe joints • Primary endpoint is reduction in contracture to wit
Slide 13: Primary Endpoint Outcome Compares Favorably To Surgery
Primary Endpoint Outcome Compares Favorably To Surgery Primary Endpoint Outcome Compares Favorably To Surgery
Slide 14: 4 Out Of 5 Dupuytren's Contracture Patients Improved By 50%
4 Out Of 5 Dupuytren’s Contracture Patients Improved By 50% > 4 Out Of 5 Dupuytren’s Contracture Patients Improved By 50%
Slide 15: Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10° Of Contracture
Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10° Of Contracture Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10° Of Contracture
Slide 16: XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications
XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications Serious Adverse Events Number Rate/Inj. Tendon / Ligament*: Confirmed Tendon Rupture 0.14% Ligament Injury 0.05% Total Tendon /
Slide 17: CORD I Key Takeaways
CORD I Key Takeaways CORD I Key Takeaways • Primary endpoint of 5° reached in 64% of patients (p<0.001) – 25 of 26 endpoints met with statistical significance of <0.001, 1 of 26 was met with a p-value = 0.002 – Of the 73 patients who didn’t respond, 44 received less than 3 injections and 25 had no p
Slide 18: Dupuytren's Commercial Opportunity
Dupuytren’s Commercial Opportunity We believe: • There is a pent-up demand for non-surgical therapy • Surgeons and patients prefer non-invasive treatment • Each patient on average has 2.2 joints which will require treatment; about half have contractures in both hands • Early data indicates on averag
Slide 19: At least 240,000 Dupuytren's Candidates In U.S. & Europe Annually
At least 240,000 Dupuytren’s Candidates In U.S. & Europe Annually Patients Seeking Treatment ~1,030,000 No Prior Surgery ~540,000 Had Surgery Previously ~490,000 Watchful Waiting ~270,000 Medical/ Surgical Treatment ~270,000 Medical/ Surgical Treatment ~125,000 Watchful Wait/ In Follow Up ~365,000 X
Slide 20: Expected Pathway to BLA Filing in Early 2009
Expected Pathway to BLA Filing in Early 2009 Expected Pathway to BLA Filing in Early 2009 • Complete 12 month open-label safety follow up from >100 CORD I patients originally randomized to XIAFLEX • Complete open-label CORD II and JOINT I/II trials to attain 1,000 patient exposure data • Finalize BL
Slide 21: Peyronie's Disease—a Devastating Disorder
Peyronie’s Disease—a Devastating Disorder 1. Smith BH. Am J Clin Pathol . 1966;45:670-678. 2. Somers KD, Dawson DM. J Urol . 1997;157:311-315. Peyronie’s Disease—a Devastating Disorder • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Sympt
Slide 22: Epidemiology—Peyronie's Disease
Epidemiology—Peyronie’s Disease Epidemiology—Peyronie’s Disease • Prevalence of Peyronie’s disease is estimated at in adult men – Actual prevalence higher based on autopsies • Prevalence rate increases with age – The average age of disease onset is years • High association with other diseases such a
Slide 23: Current Treatment—Surgical
Current Treatment—Surgical Current Treatment—Surgical • The goal of surgery is simply to make the two sides of the penis equal in size • Graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K
Slide 24: Peyronie's Disease—Unapproved Treatments Have Been Used With Little Reported Success
Peyronie’s Disease—Unapproved Treatments Have Been Used With Little Reported Success Peyronie’s Disease—Unapproved Treatments Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Ener
Slide 25: Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation
Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation > Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation Study 1030 58% 53% 35% 0% 20% 40% 60% 80% 100% Month 3 Month 6 Month 9 Study 1035 50% 100% 100% 89% 0% 20% 40% 60% 80% 100% Week 6 Mon
Slide 26: Peyronie's Phase IIb Study Enrolling Patients
Peyronie’s Phase IIb Study Enrolling Patients Peyronie’s Phase IIb Study Enrolling Patients • Study designed to assess the safety and efficacy of XIAFLEX. – XIAFLEX will be administered two times a week every six weeks for up to three treatment cycles (2 x 3) – ~120 patients – ~11 U.S. sites • Patie
Slide 27: Peyronie's Phase IIb Study Design
Peyronie’s Phase IIb Study Design Peyronie’s Phase IIb Study Design • Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling. no Placebo D no XIAFLEX C yes Placebo B yes XIAFLEX A Targeted Number of Patients Plaque Modeling S
Slide 28: Peyronie's Phase IIb Patient Reported Outcome (PRO)
Peyronie’s Phase IIb Patient Reported Outcome (PRO) Peyronie’s Phase IIb Patient Reported Outcome (PRO) • Study is also designed to validate a proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. • PRO will measure four domains of patients’ sexual quality of life, over a 36 week peri
Slide 29: At least 210,000 Peyronie's Candidates In U.S. and Europe Annually
At least 210,000 Peyronie’s Candidates In U.S. and Europe Annually Patients Seeking Treatment ~475,000 Surgery Not Recommended ~365,000 Watchful Waiting ~160,000 Medical or Intralesional Therapy ~205,000 Surgery Recommended ~110,000 XIAFLEX Potential Candidates or 67% of Medical/ Surgical candidates
Slide 30: Testim is the Fastest Growing Testosterone Replacement Therapy Gel
Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel • Proprietary, topical 1% testosterone gel – Once-a-day application – Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45
Slide 31: 447% +30%
447% +30%
Slide 32: Gels Fastest Growing TRT Segment
Gels Fastest Growing TRT Segment Gels Fastest Growing TRT Segment Source: IMS data ($ in millions) Gel Patch Oral Injectables $35 $117 $200 $287 $340 $383 $449 $459 $399 $302 $210 $77 $59 $49 $499 $118 $568 Gel Segment Growth ($) Jun 2008 L12M: 22.8+% Gel Segment Growth ($) Gel Segment Growth ($) Ju
Slide 33: Testim quarterly net revenues and scripts: Established Track Record of Consistent Growth
Testim ® quarterly net revenues and scripts Established Track Record of Consistent Growth $- $5 $10 $15 $20 $25 $30 $35 Net Revs TRX ® ($ in millions) Established Track Record of Consistent Growth Q2 2008 Net Revenues Y/Y Growth: +32.4% Q2 2008 Net Q2 2008 Net Revenues Revenues Y/Y Growth: Y/Y Growt
Slide 34: We Believe Testim Is Driving Growth in Overall Gel Market
We Believe Testim Is Driving Growth in Overall Gel Market Testim Share of TRx of Gel Market Source: IMS data *July 2008 gel market share of decile 8 - 10 PCPs (29.9%)* gel market share of decile 8 - 10 Urologists (41.9%)* 22.0% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% Mar-03 Aug-08
Slide 35: 2Q08 Financial Results and 2008 Guidance ($ Millions)
2Q08 Financial Results and 2008 Guidance ($ Millions) Q2 ’08 1H’08 Guidance Revenues $30.9 $58.0 $120-125 R&D Expense $13.4 $26.6 $52-56 SG&A Expense $22.2 $43.2 $88-92 Net Loss ($11.7) ($24.0) ($44-48) Stock – Based Comp Expense $2.8 $4.9 $9-11 Cash & cash equivalents $48.8 2Q08 Financial Results a
Slide 36: Strategic Priorities
Strategic Priorities Strategic Priorities • Continue Development of XIAFLEX with a plan to: – File Dupuytren’s BLA in early 2009 – Complete enrollment in Phase IIb in Peyronie’s Disease in Q1 2009 – Continue market research activities; prepare commercial team – Continue development of XIAFLEX in Pey
Slide 37: Slide 37
Auxilium Pharmaceuticals — Investor Presentation (September 2008) on 6ix